Global PARP Inhibitors Cancer Therapy Market Report 2026: Approved Therapies Dosage, Price, Sales & Clinical Trials Insight 2031
Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) -- The "Global PARP Inhibitors Cancer Therapy Market, Approved Therapies Dosage, Price, Sales & Clinical Trials Insight 2031" has been added to ResearchAndMarkets.com's offering.
The global PARP inhibitors cancer therapy market is projected to generate an opportunity exceeding USD 8 billion by 2031, supported by expanding oncology indications, precision medicine strategies, combination therapies and biomarker-guided patient selection. The market recorded an estimated compound annual growth rate of 11% and approximately 50% absolute growth between 2021 and 2025, establishing PARP inhibitors as an important segment of the global oncology therapeutics market.
Key Highlights
PARP Inhibitors Cancer Therapy Market Overview
The PARP inhibitors market exceeded USD 5 billion by 2025, driven by growing use across ovarian, breast, prostate and pancreatic cancers. These therapies have become particularly important in homologous recombination deficiency and BRCA-mutated cancers, strengthening their position within precision oncology and personalized cancer treatment strategies.
Seven leading PARP inhibitors had received approvals worldwide by May 2026. Olaparib continues to hold a leading market position, supported by its earlier commercial launch and multiple label expansions. Newer therapies, including senaparib, have also demonstrated regulatory and commercial potential. High revenue concentration, strong intellectual property portfolios, expanded indications and combination treatment strategies remain defining characteristics of the market.
The report provides a detailed assessment of approved PARP inhibitor prices, dosages, accessibility, patent life and sales performance. It also connects commercial market trends with scientific progress, regulatory developments and clinical outcomes, enabling pharmaceutical companies, investors and other stakeholders to evaluate emerging opportunities and competitive risks.
PARP Inhibitors Clinical Trials and Combination Therapy
More than 50 PARP inhibitor therapies are included in the clinical trials analysis, covering Phase I through Phase IV development. Trials are evaluated by indication, treatment combination, geography, development phase and biomarker-based patient stratification, providing a comprehensive view of the global PARP inhibitor pipeline.
Combination therapy is a major focus of current research and development. PARP inhibitors are increasingly being studied with immunotherapies, hormone therapies and other targeted treatments. Clinical research involving olaparib and pembrolizumab has reported disease control rates above 60% in selected patient populations, particularly among patients with HRD-positive tumors. Fixed-dose combinations involving niraparib, abiraterone acetate and prednisone have also attracted regulatory attention in prostate cancer, reinforcing the importance of genetic profiling and companion diagnostics.
Late-stage clinical programs are assessing PARP inhibitors in established oncology indications as well as tumor-agnostic settings defined by molecular biomarkers. Positive Phase III results, broader biomarker strategies and additional regulatory submissions could expand the addressable patient population and create new commercial opportunities through 2031.
Competitive Landscape and Leading Companies
The competitive landscape includes established pharmaceutical companies and emerging biotechnology businesses. AstraZeneca, Pfizer, GSK and Bristol Myers Squibb remain active in PARP inhibitor research, label expansion and combination therapy development. Regional companies are also strengthening the market, particularly in China, where locally developed therapies such as pamiparib and fluzoparib have received approval.
Strategic collaborations, licensing agreements and co-development partnerships continue to influence the sector by distributing development risk, expanding pipeline depth and accelerating market access. The report profiles leading companies and evaluates their market position, therapeutic focus, clinical strategy and commercial performance.
PARP Inhibitors Market Outlook Through 2031
Future market growth is expected to be supported by expanded oncology applications, companion diagnostics and new combination regimens. The use of talazoparib with enzalutamide in hormone-dependent cancers has demonstrated the potential of combination strategies to improve clinical outcomes and extend treatment opportunities.
Research into neurological and inflammatory diseases may create longer-term opportunities beyond oncology, although cancer treatment remains the principal commercial focus. Greater adoption of homologous recombination deficiency testing and other companion diagnostics is expected to improve patient selection, treatment efficiency and clinical value.
For investors, pharmaceutical companies and healthcare stakeholders, the global PARP inhibitors cancer therapy market combines established revenue streams with significant pipeline potential. Approved therapies provide commercial stability, while precision medicine, biomarker-guided treatment, expanded indications and combination therapies offer sustainable opportunities for market growth through 2031.
Key Topics Covered:
1. Research Methodology
2. Introduction to Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
2.1 PARP Inhibitors As Class Of Targeted Therapeutics
2.2 Clinical & Translational Relevance Of PARP Inhibition
2.3 PARP Enzymes As Therapeutic Targets
3. Biological Functions Of PARP In Health & Disease
3.1 Role Of PARP In Normal Cellular Physiology & DNA Repair
3.2 PARP Dysregulation In Disease Pathogenesis & Genomic Instability
3.3 Mechanisms Of PARP Inhibitor Action In Cellular Stress & Cell Death Pathways
4. Global PARP Inhibitor Market Outlook
4.1 Current Market Scenario
4.2 Future Market Opportunities
4.3 Global PARP Inhibitors Market Dynamics
5. Approved PARP Inhibitors - Clinical Overview, Dosage Pricing & Sales Insight
5.1 Clinical Overview, Pricing & Dosage Insight
5.2 Sales Insight ( 2021 -Q1'2026)
5.3 Approved PARP Inhibitors Reimbursement Policy
6. Global PARP Inhibitor Research & Market Trends by Indications
6.1 Cancer
6.2 Autoimmune & Inflammatory Diseases
6.3 Neurological Disorders
6.4 Cardiovascular diseases
6.5 Microbial Diseases
7. PARP Inhibitor Market Opportunity by Region
7.1 US
7.2 Europe
7.3 Japan
7.4 China
7.5 South Korea
8. Global PARP Inhibitors Clinical Trials Insight
8.1 Phase
8.2 Indication
8.3 Company
8.4 Country
9. Global Poly(ADP-Ribose) Polymerase Inhibitors Clinical Trials by Company, Indication & Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-II/III
9.7 Phase-III
9.8 Registered
10. Marketed Poly(ADP-Ribose) Polymerase Inhibitors Clinical insights
11. Combinations of PARP Inhibitors with Therapeutic Agents
11.1 Combination with Conventional Therapies
11.2 Combination with Radiotherapy
11.3 Combination with Targeted Therapies
11.4 Combination with Immunotherapy
12. Competitive Landscape
12.1 AbbVie
12.2 Allarity Therapeutics
12.3 AstraZeneca
12.4 BeOne Medicines
12.5 GSK
12.6 IMPACT Therapeutics
12.7 Jeil Pharmaceuticals
12.8 KuDOS Pharmaceuticals
12.9 Pfizer
12.10 Shanghai De Novo Pharmatech
For more information about this report visit https://www.researchandmarkets.com/r/zcfe2e
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.